Cara Therapeutics (CARA) Competitors $4.89 -0.06 (-1.11%) As of 10:04 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CARA vs. OPTN, ANIX, ADVM, FATE, VOR, BDTX, OCX, SNTI, ATOS, and ORMPShould you be buying Cara Therapeutics stock or one of its competitors? The main competitors of Cara Therapeutics include OptiNose (OPTN), Anixa Biosciences (ANIX), Adverum Biotechnologies (ADVM), Fate Therapeutics (FATE), Vor Biopharma (VOR), Black Diamond Therapeutics (BDTX), OncoCyte (OCX), Senti Biosciences (SNTI), Atossa Therapeutics (ATOS), and Oramed Pharmaceuticals (ORMP). These companies are all part of the "pharmaceutical products" industry. Cara Therapeutics vs. OptiNose Anixa Biosciences Adverum Biotechnologies Fate Therapeutics Vor Biopharma Black Diamond Therapeutics OncoCyte Senti Biosciences Atossa Therapeutics Oramed Pharmaceuticals Cara Therapeutics (NASDAQ:CARA) and OptiNose (NASDAQ:OPTN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, community ranking, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations. Do institutionals and insiders believe in CARA or OPTN? 44.7% of Cara Therapeutics shares are owned by institutional investors. Comparatively, 85.6% of OptiNose shares are owned by institutional investors. 3.1% of Cara Therapeutics shares are owned by insiders. Comparatively, 2.3% of OptiNose shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, CARA or OPTN? OptiNose has higher revenue and earnings than Cara Therapeutics. OptiNose is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCara Therapeutics$7.14M3.14-$118.51M-$21.01-0.23OptiNose$78.23M1.17-$35.48M-$2.88-3.16 Does the media refer more to CARA or OPTN? In the previous week, OptiNose had 3 more articles in the media than Cara Therapeutics. MarketBeat recorded 4 mentions for OptiNose and 1 mentions for Cara Therapeutics. OptiNose's average media sentiment score of 1.25 beat Cara Therapeutics' score of 0.00 indicating that OptiNose is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OptiNose 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer CARA or OPTN? Cara Therapeutics received 418 more outperform votes than OptiNose when rated by MarketBeat users. Likewise, 72.34% of users gave Cara Therapeutics an outperform vote while only 63.04% of users gave OptiNose an outperform vote. CompanyUnderperformOutperformCara TherapeuticsOutperform Votes66772.34% Underperform Votes25527.66% OptiNoseOutperform Votes24963.04% Underperform Votes14636.96% Is CARA or OPTN more profitable? OptiNose has a net margin of -41.16% compared to Cara Therapeutics' net margin of -1,099.76%. OptiNose's return on equity of 0.00% beat Cara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cara Therapeutics-1,099.76% -367.97% -107.43% OptiNose -41.16%N/A -27.42% Do analysts rate CARA or OPTN? Cara Therapeutics presently has a consensus price target of $27.84, indicating a potential upside of 468.74%. OptiNose has a consensus price target of $9.00, indicating a potential downside of 1.26%. Given Cara Therapeutics' higher probable upside, equities analysts plainly believe Cara Therapeutics is more favorable than OptiNose.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cara Therapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00OptiNose 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk & volatility, CARA or OPTN? Cara Therapeutics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, OptiNose has a beta of -0.88, suggesting that its stock price is 188% less volatile than the S&P 500. SummaryOptiNose beats Cara Therapeutics on 9 of the 16 factors compared between the two stocks. Remove Ads Get Cara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CARA vs. The Competition Export to ExcelMetricCara TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.39M$6.56B$5.40B$7.28BDividend YieldN/A2.85%4.87%4.05%P/E Ratio-0.236.8522.8817.61Price / Sales3.14194.91357.3086.64Price / CashN/A65.6738.1634.64Price / Book0.395.746.323.86Net Income-$118.51M$142.37M$3.21B$247.18M7 Day Performance-4.95%-9.71%-6.89%-6.27%1 Month Performance10.50%-12.66%-1.87%-8.87%1 Year Performance-50.60%-16.65%4.62%-6.18% Cara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CARACara Therapeutics3.3441 of 5 stars$4.90-1.1%$27.84+468.7%-54.5%$22.39M$7.14M-0.2380OPTNOptiNose2.8632 of 5 stars$9.17+0.2%$9.00-1.9%-55.8%$92.25M$78.23M-2.18190Positive NewsANIXAnixa Biosciences2.9086 of 5 stars$2.86-3.7%$9.00+214.7%-20.7%$92.08M$210,000.00-7.335Gap UpADVMAdverum Biotechnologies4.3132 of 5 stars$4.37-5.2%$27.83+536.9%-70.5%$90.91M$1M-0.73190News CoveragePositive NewsGap DownFATEFate Therapeutics3.4915 of 5 stars$0.79-7.0%$5.43+587.1%-90.3%$90.54M$13.63M-0.48550Gap DownVORVor Biopharma2.2848 of 5 stars$0.72-4.4%$8.86+1,130.2%-71.9%$89.89MN/A-0.44140Gap DownBDTXBlack Diamond Therapeutics2.5238 of 5 stars$1.55-3.7%$14.60+841.9%-69.8%$87.83MN/A-1.1790Positive NewsOCXOncoCyte2.4872 of 5 stars$3.06-4.7%$4.56+49.1%-0.7%$87.51M$1.88M-0.70120Short Interest ↑SNTISenti Biosciences2.8491 of 5 stars$3.36-2.0%$10.00+197.6%-12.0%$87.37M$2.56M-0.224Gap UpATOSAtossa Therapeutics1.7982 of 5 stars$0.67-3.3%$7.00+940.3%-68.3%$86.92MN/A-3.068ORMPOramed Pharmaceuticals1.1894 of 5 stars$2.14-3.2%N/A-21.5%$86.27M$1.34M19.4510News Coverage Remove Ads Related Companies and Tools Related Companies OptiNose Competitors Anixa Biosciences Competitors Adverum Biotechnologies Competitors Fate Therapeutics Competitors Vor Biopharma Competitors Black Diamond Therapeutics Competitors OncoCyte Competitors Senti Biosciences Competitors Atossa Therapeutics Competitors Oramed Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CARA) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CARA Stock Free CARA Stock Alerts